BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cadegiani FA, Goren A, Wambier CG, McCoy J. Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly improved COVID-19 outcomes compared to known outcomes in untreated patients. New Microbes New Infect 2021;43:100915. [PMID: 34249367 DOI: 10.1016/j.nmni.2021.100915] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
Number Citing Articles
1 Hazan S. Microbiome-Based Hypothesis on Ivermectin’s Mechanism in COVID-19: Ivermectin Feeds Bifidobacteria to Boost Immunity. Front Microbiol 2022;13:952321. [DOI: 10.3389/fmicb.2022.952321] [Reference Citation Analysis]
2 Diep P, Chaudry M, Dixon A, Chaudry F, Kasabri V. Oxytocin, the panacea for long-COVID? a review. Hormone Molecular Biology and Clinical Investigation 2022;0. [DOI: 10.1515/hmbci-2021-0034] [Reference Citation Analysis]
3 Panahi Y, Dadkhah M, Talei S, Gharari Z, Asghariazar V, Abdolmaleki A, Matin S, Molaei S. Can anti-parasitic drugs help control COVID-19? Future Virol 2022. [PMID: 35359702 DOI: 10.2217/fvl-2021-0160] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 O'Mathúna DP. Ivermectin and the Integrity of Healthcare Evidence During COVID-19. Front Public Health 2022;10:788972. [PMID: 35299698 DOI: 10.3389/fpubh.2022.788972] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Kaewduangduen W, Visitchanakun P, Saisorn W, Phawadee A, Manonitnantawat C, Chutimaskul C, Susantitaphong P, Ritprajak P, Somboonna N, Cheibchalard T, Wannigama DL, Kueanjinda P, Leelahavanichkul A. Blood Bacteria-Free DNA in Septic Mice Enhances LPS-Induced Inflammation in Mice through Macrophage Response. Int J Mol Sci 2022;23:1907. [PMID: 35163830 DOI: 10.3390/ijms23031907] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
6 Cadegiani FA, Zimerman RA, Fonseca DN, Correia MN, Muller MP, Bet DL, Slaviero MR, Zardo I, Benites PR, Barros RN, Paulain RW, Onety DC, Israel KCP, Gustavo Wambier C, Goren A. Final Results of a Randomized, Placebo-Controlled, Two-Arm, Parallel Clinical Trial of Proxalutamide for Hospitalized COVID-19 Patients: A Multiregional, Joint Analysis of the Proxa-Rescue AndroCoV Trial. Cureus 2021;13:e20691. [PMID: 34976549 DOI: 10.7759/cureus.20691] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
7 Rothrock SG, Weber KD, Giordano PA, Barneck MD. Meta-Analyses Do Not Establish Improved Mortality With Ivermectin Use in COVID-19. American Journal of Therapeutics 2022;29:e87-94. [DOI: 10.1097/mjt.0000000000001461] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 7.0] [Reference Citation Analysis]
8 Sardana K, Mathachan SR. Is there any prophylactic role for ivermectin in COVID-19-A literature summary. J Cosmet Dermatol 2022;21:24-6. [PMID: 34825774 DOI: 10.1111/jocd.14633] [Reference Citation Analysis]
9 Kelleni MT. NSAIDs and Kelleni's protocol as potential early COVID-19 treatment game changer: could it be the final countdown? Inflammopharmacology 2021. [PMID: 34822026 DOI: 10.1007/s10787-021-00896-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Bartoletti M, Azap O, Barac A, Bussini L, Ergonul O, Krause R, Paño-Pardo JR, Power NR, Sibani M, Szabo BG, Tsiodras S, Verweij PE, Zollner-Schwetz I, Rodríguez-Baño J. ESCMID COVID-19 Living guidelines: drug treatment and clinical management. Clin Microbiol Infect 2021:S1198-743X(21)00634-0. [PMID: 34823008 DOI: 10.1016/j.cmi.2021.11.007] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 25.0] [Reference Citation Analysis]
11 Popp M, Stegemann M, Riemer M, Metzendorf MI, Romero CS, Mikolajewska A, Kranke P, Meybohm P, Skoetz N, Weibel S. Antibiotics for the treatment of COVID-19. Cochrane Database Syst Rev 2021;10:CD015025. [PMID: 34679203 DOI: 10.1002/14651858.CD015025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
12 Popp M, Stegemann M, Metzendorf MI, Gould S, Kranke P, Meybohm P, Skoetz N, Weibel S. Ivermectin for preventing and treating COVID-19. Cochrane Database Syst Rev 2021;7:CD015017. [PMID: 34318930 DOI: 10.1002/14651858.CD015017.pub2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]